Credit: Macmillan Publishers Limited

Many airborne allergens have intrinsic proteolytic activity and sensing of this activity has been implicated in the initiation of allergic inflammation. Now, reporting in Nature Immunology, researchers show that rapid release and proteolytic cleavage of the alarmin cytokine interleukin-33 (IL-33) by various protease-containing allergens leads to the activation of type 2 allergic inflammation.

To study the regulation of IL-33 by allergen proteases, the authors first incubated recombinant human full length IL-33 (IL-33FL) with extracts of the major classes of environmental allergens, including fungi, house-dust mites, cockroaches and pollens. All the aeroallergen extracts showed IL-33-processing activity and generated shortened forms of the protein. Cleavage sites were confined to the central 'sensor' domain of IL-33, and some short forms of IL-33 were similar to those generated by inflammatory proteases from neutrophils and mast cells. All processed forms of IL-33 were highly active; when recombinant versions were injected intraperitoneally into wild-type mice, they induced airway inflammation, mucus production and eosinophilia, with high levels of the type 2 cytokines IL-5 and IL-13.

IL-33FL functions as a sensor of allergen proteases

The authors suggest that IL-33FL functions as a sensor of allergen proteases. Consistent with this, low doses of IL-33FL exhibited very little biological activity in vitro. Only when allergen extracts or allergen proteases were present did the authors observe potent production of IL-5 and IL-13 by cultured group 2 innate lymphoid cells (ILC2s). Accordingly, although mechanical damage to endothelial cell monolayers induced the release of IL-33FL, the generation of short forms of IL-33 required the addition of allergen proteases. Allergens without protease activity, such as phospholipase A2 from bee venom and chitin, did not generate short forms of IL-33 in these cell cultures.

Further exploring the kinetics of IL-33 cleavage in vivo, the authors show that shortly (within 15 minutes) after intranasal exposure to allergen proteases from the fungus Alternaria alternata, endogenous IL-33FL is rapidly released into the bronchoalveolar lavage fluid and then cleaved. The generation of cleaved forms could be blocked by pre-treating the A. alternate extract with the protease inhibitor α1 antitrypsin. Finally, the authors generated an antibody against the central sensor domain of human IL-33. Administration of this IL-33-blocking antibody together with the allergen to Il33−/− mice reconstituted with human IL-33FL reduced IL-5 levels and airway inflammation.

This study identifies an important molecular mechanism for the induction of allergic inflammation based on the sensing of allergen-associated proteolytic activity by IL-33.